Treatment for COVID-19 in High-Risk Adult Outpatients

Inclusion Criteria: * Men or women 18 to 80 years of age, inclusive, at the time of signing the informed consent * Willing and able to provide informed consent * Laboratory confirmed SARS-CoV-2 infection, with test results within past 72 hours * COVID-19 symptoms, based on the following criteria: At least TWO of the following symptoms: Fever (≥ 38ºC), chills, rigors, myalgia, headache, sore throat, new olfactory and taste disorder(s), OR o At least ONE of the following symptoms: cough, shortness of breath or difficulty breathing (Lopinavir-Ritonavir Platform) * Access to device and internet for Telehealth visits * At increased risk of developing severe COVID-19 disease (at least one of the following) 1. Age ≥60 years 2. Presence of pulmonary disease, specifically moderate or severe persistent asthma, chronic obstructive pulmonary disease, pulmonary hypertension, emphysema 3. Diabetes mellitus (type 1 or type 2), requiring oral medication or insulin for treatment 4. Hypertension, requiring at least 1 oral medication for treatment 5. Immunocompromised status due to disease (e.g., those living with human immunodeficiency virus with a CD4 T-cell count of \<200/mm3) 6. Immunocompromised status due to medication (e.g., persons taking 20 mg or more of prednisone equivalents a day, anti-inflammatory monoclonal antibody therapies, or cancer therapies) 7. Body mass index ≥30 (self-reported) Exclusion Criteria: * Known hypersensitivity to HCQ or other 4-aminoquinoline compounds * Known hypersensitivity to azithromycin or other azalide or macrolide antibiotics * Currently hospitalized * Signs of respiratory distress prior to randomization, including respiratory rate \>24 * Current medications include HCQ * Concomitant use of other anti-malarial treatment or chemoprophylaxis * History of retinopathy of any etiology * Psoriasis * Porphyria * Chronic kidney disease (Stage IV or receiving dialysis) * Known bone marrow disorders with significant neutropenia (polymorphonuclear leukocytes \<1500) or thrombocytopenia (\<100 K) * Concomitant use of digoxin, cyclosporin, cimetidine, amiodarone, or tamoxifen * Known cirrhosis * Known personal or family history of long QT syndrome * History of coronary artery disease with a history of graft or stent * History of heart failure, Class 2 or greater using the New York Heart Association functional class * Taking medications associated with prolonged QT and known risk of torsades de points. These medications may include some antipsychotic and antidepressant medications. (Lopinavir-Ritonavir Platform) * Taking medications associated with prolonged QT such as antipsychotic medications or antidepressants (e.g., citalopram, venlafaxine, and bupropion) and unable to stop during the trial * Taking warfarin (Coumadin or Jantoven) * Known history of glucose-6-phosphate-dehydrogenase deficiency * History of myasthenia gravis